Login to Your Account



XenoPort Shares Collapse After FDA Rejects RLS Compound

By Donna Young


Friday, February 19, 2010
Shares of XenoPort Inc. lost two-thirds of its value Thursday after the firm revealed that its partner GlaxoSmithKline plc had received a complete response letter from the FDA for its application for Horizant (gabapentin enacarbil), also known as GSK1838262 or XP13512, for moderate to severe primary restless legs syndrome (RLS). (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription